Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice

Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice

The anti-diabetic and anti-obesity effects of the allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor 4-(biphenyl-4-ylmethylsulfanylmethyl)-N-(hexane-1-sulfonyl)benzoylamide (KY-226) were pharmacologically evaluated. KY-226 inhibited human PTP1B activity (IC50 = 0.28 μM), but did not exhibi...

Full description

Bibliographic Details
Main Authors: Yuma Ito, Masaki Fukui, Mamoru Kanda, Ko Morishita, Yoshimichi Shoji, Tatsuya Kitao, Eiichi Hinoi, Hiroaki Shirahase
Format: Article
Language:English
Published: Elsevier 2018-05-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861318300422

Internet

http://www.sciencedirect.com/science/article/pii/S1347861318300422

Similar Items